Ladies and gentlemen, thank you for standing by, and welcome to Alnylam Pharmaceuticals’ Conference Call to discuss Q4 and Year-end 2013 Financial Results. There will be a question-and-answer session to follow. Please be advised that this call is being taped at the company’s request. I would now like to turn the call over to the company.

Good afternoon. I’m Cynthia Clayton, Vice President of Investor Relations and Corporate Communications at Alnylam. With me today are John Maraganore, our Chief Executive Officer; Barry Greene, President and Chief Operating Officer; Akshay Vaishnaw, Executive Vice President and Chief Medical Officer; and Mike Mason, Vice President of Finance and Treasurer. Laurence Reid, our Chief Business Officer, is also here and available for Q&A. For those of you participating via conference call, the slides we have made available via webcast can also be accessed by going to the “Investors” page of our website, at www.alnylam.com. During today’s call, as outlined in slide two, John will provide some introductory remarks and provide general context for some of our recent progress and activities. Akshay will summarize the clinical progress with our Alnylam 5x15 pipeline. Mike will review our financials and guidance. And Barry will provide a brief summary of our business highlights and goals for 2014, before we open up the call to your questions. Before we begin, I would like to remind you that this call will contain remarks concerning Alnylam’s future expectations, plans and prospects, which constitute forward-looking statements for the purposes of the Safe Harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recent quarterly report on file with the SEC. In addition, any forward-looking statements represent our views only as of the date of this recording and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligations to update such statements. I’ll now turn the call over to John.

Thanks, Cynthia, and welcome, everyone, and thanks for joining us this very snowy afternoon up here in Boston. The full year 2013 and the first weeks of 2014 were transformational for Alnylam and our continued efforts to advance RNAi therapeutics as a whole new class of medicines. Indeed, we believe our recent alliance with Genzyme is a game changer for both the advancement of RNAi therapeutics as a new class of genetic medicines to patients around the world and also for our commitment to build a leading, independent biopharmaceutical company that delivers value to our shareholders. This alliance provides Alnylam with expanded development and commercial opportunities for our Alnylam 5x15 pipeline and also our broader genetic medicine pipeline through Genzyme’s established global infrastructure, commitment and proven track record in rare diseases. Moreover, this alliance crystallizes Alnylam’s strategy to develop and commercialize our products in North America and Western Europe, while Genzyme advances our products in the rest of the world. And as you’ll hear from Mike in just a minute, it also solidifies our balance sheet, enabling an increased investment in an expanded number of RNAi therapeutic programs while securing a cash runway that we believe provides us with financial independence to develop and launch multiple products. As many of you are aware, our Alnylam 5x15 product strategy establishes a path for development and commercialization of novel RNAi therapeutics as genetic medicines. That is to say RNAi therapeutics directed toward genetically defined targets for the treatment of diseases with high unmet medical need. Since the launch of our Alnylam 5x15 product strategy in 2011, we have made tremendous progress and we now expect to significantly exceed our original goals. Indeed, we now expect to end 2015 with six to seven programs in clinical development, including at least two programs in Phase III and five to six programs having achieved human proof-of-concept results. In addition, with the now nine active and disclosed genetic medicine programs that we have in our pipeline, there are about a dozen more that you have yet to hear about. The reason for our accelerated productivity should be increasingly clear. Once we establish robust and well-tolerated delivery of RNAi therapeutics to deliver, especially with our GalNAc conjugate platform that enables subcutaneous delivery with a wide therapeutic index and confirmed this with clinical validation, we’ve been able to establish the beginnings of a modular and reproducible platform for genetic medicines. Overall, we’re very pleased with the continued execution on our Alnylam 5x15 product strategy over the last several months including initiation of new Phase I, Phase II, and Phase III clinical trials across three distinct programs and we expect to have multiple data readouts in 2014. In sum, we believe that our recent business and clinical accomplishments strengthen our efforts to build a leading independent biopharmaceutical company that delivers value to our shareholders. I’ll now turn the call over to Akshay, our Chief Medical Officer who will highlight some of our important clinical progress of recent days. Akshay?

Thank you, John. The past 13 months represent a period of remarkable execution on our clinical pipeline as we continue to deliver on the promise of RNAi therapeutics with notable clinical results and pipeline progress. I’ll start with an update on patisiran. As most of you are aware, patisiran is a lead 5x15 program and is aimed at the treatment of TTR-mediated amyloidosis or ATTR patients with familial amyloidotic polyneuropathy of FAP. Our highlight in this past quarter was the initiation of our APOLLO Phase III trial with patisiran and the company’s first ever Phase II study. This is a very significant milestone in our history and also for the entire field of RNAi therapeutics. The APOLLO trial is a randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of patisiran in ATTR patients with FAP. The primary endpoint of the study is the difference in the change in a Neuropathy Impairment Score called mNIS+7 between patisiran and placebo at 18 months. In addition, there are a number of important secondary endpoints including quality of life. The study is actively enrolling patients across a great number of sites and accrual in the study is a major focus for Alnylam in 2014. The strong Phase II data from this program is what gave us confidence to advance patisiran into the APOLLO Phase III study. As presented at the ISFAP meeting in November and as you can see on slide eight, our Phase II results showed in up to 96% knockdown of serum TTR in ATTR patients. Patisiran activity was found to be rapid, dose-dependent and durable with similar levels of TTR knockdown observed towards both wild-type and mutant protein. And patisiran was found to be generally well tolerated. Patients who are in the Phase II study have rolled over into…

Thanks, Akshay. I’ll be referring to slide 17 for a discussion of our Q4 and year-end 2013 financial results. Alnylam continues to maintain a very strong balance sheet, ending the fourth quarter of 2013 with $350 million in cash, cash equivalents and marketable securities. Our GAAP revenues for the fourth quarter of 2013 were $10.8 million as compared to $8.5 million in the fourth quarter of 2012. Revenues this quarter included $5.5 million related to our collaboration with Takeda, $1.4 million related to our collaboration with Monsanto and $3.9 million related to our collaboration with the medicines company as well as research reagent licenses and other sources. Looking ahead, GAAP revenues related to the recent Genzyme alliance will be amortized over approximately 20 years and include the premium on the stock purchase at closing as well as any deferred revenue remaining from the 2012 alliance. Moving to expenses, R&D expenses were $32.1 million this year as compared to $21.7 million in the prior year period. The increase was due to license fees related to the initiation of the Phase III trial of patisiran and an increase in compensation related expenses, including stock-based compensation. Looking ahead, we expect R&D expenses to increase significantly as we continue to develop our pipeline and advance our product candidates in clinical trials. G&A expenses were $8.3 million in the fourth quarter of 2013 as compared to $10.2 million in the fourth quarter of 2012. The decrease in G&A expenses as compared to the prior year period was due primarily to a decrease in consulting and professional services related fees related to business and legal activities. We expect G&A expenses to increase slightly in 2014. Looking ahead to the first quarter, we expect to record a significant charge to operating expenses in connection with our acquisition of Sirna which we expect to close in the first quarter of 2014. The expected total amount of this expense will be based on a cash payment of $25 million as well as the value of 2.5 million common shares that we will issue to Merck upon closing multiplied by our closing price of our common stock at the closing of the transaction. Following the close of our new alliance with Genzyme, our balance sheet will be over $1 billion on a pro forma basis which will allow us to increase our investment in new RNAi therapeutic programs while securing a cash runway for many years to come that we believe will allow us to develop and launch in multiple products. With respect to guidance for 2014, we expect we’ll finish the year with greater than $825 million in cash, which provides us with a strong balance sheet to execute on our business plan and advance our RNAi therapeutics through clinical trials and towards the market. I will now turn the call over to Barry.

Thanks Mike. As you heard from John and Akshay, we had a tremendously productive 2013 in recent period. We’re delighted, kicking off 2014 with the expansion of our Genzyme partnership. We also had some other important business news at the start of the year, including our agreement with Merck to acquire Sirna Therapeutics. Specifically, we have agreed to acquire the entirety of Merck’s RNAi assets including their wholly-owned Sirna Therapeutic subsidiary. As you may recall, Merck acquired Sirna in 2006. Following that acquisition, Merck scientists made significant advances in siRNA chemistry and delivery including with GalNAc-siRNA conjugates which we view to be the best-in-class approach for the delivery of RNAi therapeutics. Our acquisition of Sirna brings those assets and technologies to Alnylam in a manner that accelerates and advances our overall efforts in RNAi therapeutics. In addition, we obtained over 125 issued patents from the Sirna acquisition in addition to some later stage preclinical assets. Now, turning our 2014 goals and guidance, as we announced at the start of the year, and as John commented earlier, we now expect to significantly exceed our original 5x15 guidance. Our Alnylam 5x15 strategy, which we launched in early 2011, stated that we expected to have five programs in clinical developments by 2015. We now expect to significantly exceed that guidance with six to seven programs in clinical development by the end of 2015, which includes at least two programs in Phase III and five to six programs that will have achieved human proof-of-concept results. As you can see on slide 20, we view the year as one that promises to bring us closer to the market with our Phase III trials, yield multiple data readouts that provide expanded proof-of-concept and broaden our opportunities with a significant growth in our clinical pipeline, a potential…

(Operator Instructions) Our first question comes from Geoff Meacham of JPMorgan. Your line is now opened. Geoff Meacham – JPMorgan: Good afternoon, guys. And thanks for taking the question and congrats on all the progress.

Thank you, Geoff. Geoff Meacham – JPMorgan: I know it just happened but where are you guys on the integration of Merck’s Sirna programs and what’s your initial view of the targets or differences in the tech platform? And I have one follow-up.

Yeah, so, Geoff, we obviously, as part of the acquisition, we did extensive due diligence, but until the deal closes, we’re only in planning stages around any integration activities. Obviously the deal has to close before we can integrate the technologies. But what’s clear to us obviously is that there are two dimensions of important things that the acquisition brings to Alnylam. One is the fact that we, of course, get access to additional intellectual property that was in Merck’s hands. That really continues to help Alnylam build and expand our pipeline, advancing medicines to patients. But the second part of it and perhaps the most exciting part of it is the technology that Merck scientists developed over the years, following their acquisition of Sirna. And that technology, particularly the technology around conjugates and siRNA delivery, when added to the Alnylam GalNAc conjugate platform, really goes a long, long way to continue to optimize that platform for the future and for Alnylam’s efforts. So very exciting when we obviously close a deal, we’ll fully integrate all of this but clearly, what we believe we have access to in that acquisition is a very powerful array of technologies but also intellectual property. Geoff Meacham – JPMorgan: Okay. That’s helpful. And then for the APOLLO study, I was just curious about the natural history, just with respect to the volatility of disease progression say over the 18 months of the trial. And if you guys can talk about any background meds or interventions that can be used over the study, that would be great? Thanks.

Yeah. Akshay, you want to handle that?

Yeah, Geoff, we have a pretty good understanding of the natural history of this disease, both from literature as well as from the placebo arms in the tafamidis and [inaudible] most importantly, data we collected both from the U.S. and Europe across very significant triple digit number of patients with a variety of mutations. So I think we’ve got a good handle on the increasing in Amyloidosis expected overtime in terms of factors that influence Amyloidosis of course in the context of this study, it’s a placebo-controlled study. So they won’t be on any other potentially disease-modifying treatment. And in that respect, really, the only thing to consider is tafamidis the approved drug in the EU and that’s not allowed in course of our study of course. So I think we’ve got a pretty, pretty good handle on the design of the study the way we’ve padded the increase in the near occupancy listing.

And I would just add, Geoff, that everything Akshay said is spot on, of course. But we’ve also stratified enrollment for a number of known factors that correlate with changes or differences in disease progression. That includes age; it includes genotype and other variables, as well. So the stratification has been an important element, too. Geoff Meacham – JPMorgan: Got you. Okay. Thanks.

Yes, thanks, Geoff.

Thank you. Our next question comes from Alethia Young of Deutsche Bank. Your line is now opened. Alethia Young – Deutsche Bank: Hey, guys, congrats on all of the progress.

Thanks, Alethia. Alethia Young – Deutsche Bank: And I just have two questions. One is going to be housekeeping and the other one is about FAC. So with the FAC I’m just wondering if you can help us think about how we – expectations on the Phase II coming up. You’re studying a lot of things beyond TTR knockdown, but just kind of help us with our expectations there. And then my second question is just on the share count, does it go up by roughly by 11 million shares when the Genzyme deal closes? Thanks.

That’s exactly right. We’ll have right around 75 million shares outstanding after both deals close.

And so then turning to FAC. Akshay, you want to handle that?

Yeah. So with respect to the Phase II study, Alethia, I think the most important elements for us and for the Phase III effort that should start by the end of the year will demonstrate safety in the context of this Phase II study, TTR knockdown as you mentioned, obviously pharmacokinetics is another major element. So those three are key, and I think we are very confident around those and that will guide us to the Phase III study. The other elements that we’re measuring, of course, to try and demonstrate over time potentially preliminary clinical activity of things like changes in cardiac biomarkers, BNP and troponin amongst others, echocardiogram, and other measures, clinical measures such as 6-minute walk and quality of life questionnaire. And many of these will be carried over into subsequent study when these patients get rolled over into a long-term extension study. And so we’ll have the benefit of studying these patients over a long period of time and be able to evaluate many factors beyond just TTR knockdown. But certainly for this year, I think the focus is, let’s demonstrate TTR knockdown safety and PK and use that knowledge to guide the Phase III.

Yeah. And I think it’s important, Alethia, that these exploratory, clinical endpoints are, in fact, exploratory. And I think in the course of this year, where patients will be exposed on a limited basis to drug treatment, I’d be surprised if we see changes on those endpoints that are of note. But we’ll certainly report all the data when we report the data later in the year. Alethia Young – Deutsche Bank: Okay. Can I sneak in one other one?

Yes, please. Alethia Young – Deutsche Bank: Okay. So when you think about…

Your first one was very short. So that was a half like two and a half. Yeah. Alethia Young – Deutsche Bank: Awesome. So when thinking about FAC pricing, I know it’s early. So when you’re thinking about going into a Medicare population predominantly and kind of an orphan drug pricing, how do you reconcile all of that in your mind?

Yeah. Alethia Young – Deutsche Bank: What are your initial thoughts?

It’s a great question. Barry, do you want to handle it?

Yeah. So, Alethia, as we have discussed, we think that when we look at the FAC population and the opportunities that we’re developing to intervene earlier in the disease and the number of patients that the pharmaco-economics for orphan-like pricing – and as we develop the data, we’ll share more thoughts on that, as the Phase III gets going and we get closer to market.

I mean, clearly, there is a significant cost in the management of these patients. The burden of heart failure and the implications are quite significant, quite expensive. And obviously that’s going to be a core part of the argument that we ultimately make, if our data supports the efficacy level that we expect to achieve. Alethia Young – Deutsche Bank: Great. Thanks, guys. Congrats.

Good. Thank you.

Thank you. Our next question comes from Alan Carr of Needham & Company. Your line is now opened. Alan Carr – Needham & Co.: Hi. Thanks for taking my questions.

Hey, Alan. How are you? Alan Carr – Needham & Co.: I’m good. Thank you. The first is on the burn for 2014. It looks like you’re aiming for around $200 million. I wonder if you could comment upon that and then if I have that right. And then, also, at what point, do we start to see a contribution from Sanofi in terms of covering R&D? And then also I am wondering if you could comment a bit on a couple of the newer programs that you all have disclosed, the AAT and ANG, a bit more about the opportunities there. Thanks.

All right. So Mike, you want to handle the first part and Akshay and I will handle the second.

Sure. So, Alan, you’re correct. We finished the year with $350 million. If you add in the proceeds from Genzyme upon closing, it takes us over $1 billion in cash and we’re guiding greater than 825. A little color on that, we mentioned that we expect G&A expenses to increase slightly in 2014. We will make a cash payment of $25 million to Merck upon that deal closing and results the other things. But everything else that makes up that $200 million or so burn is related to R&D expenses to drive our program forward. And your second part of your question was, when do we expect the contribution from Genzyme from an R&D reimbursement perspective. That will start beginning in 2015.

Yes, that was one of the terms in the agreement that that reimbursement would be started in 2015. But then getting on to your other question, Alan, these are two really exciting programs that are moving through our pipeline. They are certainly candidates for potential INDs in 2015 as they stand right now. One is our alpha-1 antitrypsin program. This is a, again, a function genetic disease in the liver where expression of the genetic – the mutated form of alpha 1 antitrypsin results in a liver injury and a liver fibrosis that ultimately, if untreated, can lead to cirrhosis and the need for liver transplant, if it’s available in these patients. Very high on unmet need. About 10,000 patients that are known in U.S. and Western Europe in the system, very interesting opportunity by all accounts, very clearly validated genetically. And then the ANG program is a terrific target. It’s a protein that’s involved in both endothelial lipase as well as lipoprotein lipase activity it’s been genetically validated in GWAS studies where mutations are associated with increased risk of cardiovascular disease. And clearly, the knockdown of this target in our preclinical studies are associated with over 95% decreases in trig levels, in animal models, with well over 50% decrease of LDL cholesterol. So the setting that we’re interested in here would be severe forms of mixed hypertriglyceridemia and mixed hyperlipidemia where these patients are at risk for significant pancreatic – pancreatitis and other cardiovascular risk factors. Akshay, anything to add?

No. I think you’ve covered that very nicely, John. Thank you.

Thank you. Alan Carr – Needham & Co.: Thanks very much.

(Operator Instructions). Our next question comes from Mike King of JMP Securities. Your line is now opened. Michael King – JMP Securities: Hey, guys, thanks for taking the questions. If I keep all of my questions short, can I just keep going?

How are you, Mike? Michael King – JMP Securities: I’m good, thanks. Just a couple of technical questions. I just wanted to know, remind us if there is a hard cover aspect to the Sirna acquisition and is there any concern on your part at all about FTC, you know, issues blocking it or requiring divestiture or other methods to complete the acquisition?

So, Laurence, do you want to handle that?

So, yes. Hi, Mike. Yes, that process is ongoing. We filed together with Merck for the clearance awhile back and that process is ongoing. And obviously, we’ll respond to any questions we get asked but we have no significant concerns. We put together the appropriate process with Merck, so we’re completely optimistic that that will close hopefully in the relatively near future. As John mentioned a few minutes ago, we want to integrating and advancing that technology. Michael King – JMP Securities: Okay. And then, I guess a clinical question for either Akshay or Barry. In FAC, you said you’re also going to enroll individuals with; A, just wondering if there’s any difference between SSA and FAC or if there’s any different progression or presentation, et cetera.

Yeah. Those diseases are very similar. FAC is mutation-based TTR cardiomyopathy. The most common mutation predisposing to that is this mutation density 122I which is prominent in African Americans, although in many others as well. And the majority of those patients, particularly the V122I patients will present in their 60s with heart failures and go on to have this dysrhythmia, diastolic dysfunctions. Sadly, the mean survival is of the order of two to four years. The SSA patients have a TTR cardiomyopathy that mediated by wild-type TTR. They tend to present a few years later, typically late 60s, 70s but you know, they’re very similar clinical echocardiographic biopsy and other features in their clinical course tends to run true in parallel to what I described for FAC, and the median survival there is also pretty poor. So they’re more alike than different, and most people think of them very similarly. Michael King – JMP Securities: Okay. So there is not going to be any confusion about the readout when the studies – when the Phase IIs are over?

No. The kinds of readout – everything from the biomarker aspect such as BNP and troponin are commonly utilized in the study of dose-free cardiomyopathy. The echo, cardiac MRI, technetium scan and a variety of other images modalities are commonly used in both settings. And then, of course, the very sort of concrete clinical endpoint, 6-minute walk test, hospitalization, mortality are kind of stuff that’s used in heart disease. So there is a plethora of things to choose from there. And we’re working hard to define the details of our Phase III study. Michael King – JMP Securities: Okay. All right. I’ve got some others, but I’ll jump back in queue and give some other people a shot. Thank you.

Thanks, Mike.

Thank you. And our next question comes from David Friedman of Morgan Stanley. Your line is now opened. Brienne Kugler – Morgan Stanley: Hi. This is Brienne calling in for Dave. Thanks for taking my call.

Hi, Brienne. How are you? Brienne Kugler – Morgan Stanley: I’m good. How are you, guys?

Good. Brienne Kugler – Morgan Stanley: Just a quick question on the ALN-TTRsc Phase II program. So will you be doing MRI or other imaging to look at amyloid changes in the heart?

Yes. We will. And I think as we were discussing earlier with Alethia, although the focus this year in terms of data will be safety and TTR knockdown, etcetera, to guide the Phase III, those endpoints will be more important and interesting to follow in the long run as those patients roll over into the open label extension study corresponding to the Phase II program. Brienne Kugler – Morgan Stanley: Thanks.

Thank you.

Thank you. And our next question comes from Mike King of JMP Securities. Your line is now opened. Michael King – JMP Securities: Wow, that was quick.

That was quick. Michael King – JMP Securities: So I just wanted to ask Mike about the commentary about G&A because it seems to me like your G&A ought to be going up more since you’re going to be ramping up, you know, more advanced programs with larger patient numbers, if you push forward with some of the other pipeline like whatever TMP. That costs money, as well, so I’m just wondering how you get away with that.

Mike, you mean G&A or R&D? Michael King – JMP Securities: Well, I guess, both, because, I mean, you need…

Well, R&D definitely. That’s going to go up.

Mike, the main components of our G&A expenses are clearly public company costs and costs to support our IP portfolio, so we do expect certainly a slight increase in 2014 as the company grows with that. But from an R&D perspective, as I mentioned, we certainly expect a significant increase in 2014 to support all of these newer programs as well as the more advanced programs. Michael King – JMP Securities: Okay. So just – so then to be clear, any headcount, the majority of any headcount increases would go through R&D and not G&A.

That’s correct. Michael King – JMP Securities: Okay.

We keep a relatively flat G&A in this company and again, I think the only notable place where there will be an increase and a slight increase relates to the increased costs on the IP portfolio from the Sirna acquisition when that closes. Michael King – JMP Securities: Okay. Right, right, fair enough. And then just as far as the – John, your commentary about proof-of-concept. Just to be clear, how you guys are going to – are you going to continue to look at it in sort of the same way that you have to-date, meaning I guess knockdown gene expression and reduction of culprit protein or are you at some point going to raise the bar as to what you guys consider to be proof-of-concept of your clinical candidates?

Well, we’ve already raised the bar and so when we talk about the five to six human proof-of-concept data points that we expect to have, it would be things like – in the case of TTR, its knockdown of this disease-causing protein. But in the case of a program like PCSK9, it is LDL reductions. In a case of a program like hemophilia program, it’s increased thrombin generation. Okay? In the case of our C5 program, it’s demonstrating that subjects treated with ALN-CC5 but their serum does not like PNH to recur size. All right. So these are the types of POC data points that are very de-risking as it relates to the fundamental program advanced into Phase III toward approval. Michael King – JMP Securities: Got it, got it. Extremely helpful. Thanks, guys.

Thank you.

Thank you. And our next question comes from Stephen Willey of Stifel. Your line is now opened. Stephen Willey – Stifel Nicolaus & Co.: Yeah, hi, guys. Thanks, for sneaking me in.

Hi, Steve. How are you? Stephen Willey – Stifel Nicolaus & Co.: I’m doing well. How are you?

Good. Stephen Willey – Stifel Nicolaus & Co.: Just a quick question, I guess, regarding FAC and maybe just – what’s the level of comfort right now just around what a Phase III needs to look like, I guess, specifically in terms of functional endpoints that FDA might want to see. And I guess, just given the fact that the Phase II data I think is being targeted as a late 2014 event, which I guess overlaps with the start of a Phase III. Should we expect to get that data in conjunction with trial design specifics on a Phase III? Thank you.

Yeah. Akshay, do you want to handle…?

Yeah, sure…

The first part? I can sort of handle the second part.

The design of the Phase III, Steve, I mean, it’s February. We’re still in the thick of it. We’re confident, based on precedent and also literature that there are a number of ways to attack this. And also remembering it’s an awful indication. So I think it’s a little premature to get into what the primary endpoint design might be. We certainly will – as we did for the FAP indication later in the year, we will be sharing it. But, as we were discussing earlier on the call, the plethora of end points to think about here. The cardiac biomarkers they have shown to be responsive in changes in heart failure, things like BNP and troponin. They’re certainly responsive in other amyloidotic cardiomyopathies like AL cardiomyopathy. The echo technician scan and other imaging modalities as cardiac MRI, many have them have key characteristics on TTR cardiomyopathy so that’s important to think about. And then, as you mentioned, there are conventional clinical end points as well. So we’re working through all of that, more details to come.

Yeah. We’ll be obviously talking to the FDA and EMA about those trial designs and getting alignment with them with end of Phase II meetings and scientific advice meetings as well. But then in terms of how the news flow will work, Steve, that too is too early to tell. Obviously we’ll aim to present the Phase II data at a scientific or clinical meeting towards the end of the year. We’ll have those data in our hands at least in advance of presenting them. So those data are going to be useful in our dialogue with the FDA and EMA or at least some of those data, not necessarily all the data. And stay tuned. I mean, I think, it’s still too early in the year to say exactly where and how we’ll do it, but we will do it. Stephen Willey – Stifel Nicolaus & Co.: Okay. And so, I guess, with respect to the open-label extension part of the study starting, I think, in mid ‘14.

Yeah. Stephen Willey – Stifel Nicolaus & Co.: And then, presumably, I guess, you would need to get something on the calendar with respect to FDA regarding an end of Phase II. So do you think, I guess, having a less than six months of open-label extension data around what could be exploratory endpoints would be sufficient at this point?

Yeah. I mean, we think the therapeutic hypothesis that is going to be evaluated in the Phase III is going to be very well supported by the time we have our discussions with the FDA both in terms of patient exposure – keep in mind, we’re also obviously finalizing and completing our chronic tox studies in non-clinical species to support long-term dosing in our Phase III trial. And that’s ongoing as well. So there is a lot of other stuff. And we’re also, of course, ramping up our GNP production to get to a scale and final process that will support the Phase III dosing as well. So these are all things that go on behind the scenes that nobody ever seems to understand. But it’s part of the heavy lifting that we do before we go into the Phase III. Stephen Willey – Stifel Nicolaus & Co.: Fair enough. I appreciate the color, and congrats on the great year.

Yes. Thanks, Steve. So go ahead.

And I’m show nothing further questions at this time.

Okay. Well, look, thanks, everyone for joining us on this snowy afternoon. We fully expect that 2014 will be another exciting year for Alnylam. We’re off to a great start. But we look forward to updating you as the year progresses. Have a good and safe rest of the day. Bye-bye.